<DOC>
	<DOCNO>NCT02935257</DOCNO>
	<brief_summary>This multi-centre , non-randomised , open label Phase I clinical trial Advanced Therapy Investigational Medicinal Product ( ATIMP ) adult ( age 16 65 year ) high risk , relapsed/refractory CD19+ B-ALL . The ATIMP study cryopreserved autologous patient-derived T-cells transduce lentiviral vector generate CD19CAT-41BBZ CAR T-cells ( refer subsequently CD19CAR T-cells ) . Patients undergo unstimulated leucapheresis generation ATIMP take approximately 15 day generate . During period , patient may receive `` hold '' chemotherapy per institutional practice maintain disease control . Patients receive pre-conditioning lymphodepleting chemotherapy cyclophosphamide 60mg/kg Day -6 fludarabine 30mg/m2 administer 3 day ( Day -5 Day -3 ) . The study design intra-patient dose escalation employ total dose range ( 2 dos , Dose 1 Dose 2 ) 5 x 106 CD19CAR T-cells 1.1 x 109 CD19CAR T-cells . The study evaluate ATIMP safety efficacy duration disease response adult high risk / relapse CD19+ B-ALL . After complete interventional phase study patient , irrespective whether progressed respond treatment , enter long term follow 5 year post-CD19CAR T-cell infusion .</brief_summary>
	<brief_title>Immunotherapy High Risk/Relapsed CD19+ Acute Lymphoblastic Leukaemia Using CAR T-cells Target CD19</brief_title>
	<detailed_description>This multi-centre , non-randomised , open label Phase I clinical trial Advanced Therapy Investigational Medicinal Product ( ATIMP ) adult ( age 16 65 year ) high risk , relapsed/refractory CD19+ B-ALL . The ATIMP study cryopreserved autologous patient-derived T-cells transduce lentiviral vector generate CD19CAT-41BBZ CAR T-cells ( refer subsequently CD19CAR T-cells ) . Patients undergo unstimulated leucapheresis generation ATIMP take approximately 15 day generate . During period , patient may receive `` hold '' chemotherapy per institutional practice maintain disease control . Patients receive pre-conditioning lymphodepleting ( LD ) chemotherapy cyclophosphamide 60mg/kg Day -6 fludarabine 30mg/m2 administer 3 day ( Day -5 Day -3 ) . The study design intra-patient dose escalation employ total dose range ( 2 dos , Dose 1 Dose 2 ) ( minimum ) 5 x 106 CD19CAR T-cells ( plus 20 % thawing loss ) ( maximum ) 1.1 x 109 CD19CAR T-cells ( plus 20 % thawing loss ) . The initial ATIMP dose administer dependent upon B-ALL disease burden bone marrow . For patient &lt; 20 % marrow infiltration B-ALL baseline ( screen ) , Dose 1a 1x108 CD19CAR T-cells administer Day 0 follow LD . For ≥20 % marrow infiltration B-ALL , Dose 1b , administer Day 0 , 1x107 CD19CAR T-cells . This measure prevent toxicity keep publish data correlate severity CRS disease burden . Dose 1a* ( BM blasts≤20 % ) : 1x108 CD19CAR T-cells ( plus 20 % thawing loss ) Dose 1b* ( BM blast &gt; 20 % ) : 1x107 CD19CAR T-cells ( plus 20 % thawing loss ) Dose 2* ( patient , absence clinically severe CRS ) : dose range minimum dose ≥5 x 106 CD19CAR T-cells ( plus 20 % thawing loss ) maximum dose ≤1x109 CD19CAR T-cells ( plus 20 % thawing loss ) *Minimum dose permitted trial Dose level ≥5 x 106 CD19CAR T-cells ( plus 20 % thawing loss ) The study evaluate ATIMP safety efficacy duration disease response adult high risk / relapse CD19+ B-ALL . After complete interventional phase study patient , irrespective whether progressed respond treatment , enter long term follow 5 year post-CD19CAR T-cell infusion .</detailed_description>
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Precursor Cell Lymphoblastic Leukemia-Lymphoma</mesh_term>
	<mesh_term>Leukemia , Lymphoid</mesh_term>
	<criteria>1 . Adults ( age range 16 65 year ) high risk/relapsed histologically confirm CD19+ BALL follow standard therapy measurable disease require salvage alternative therapy deem inappropriate treating physician . 2 . Agreement pregnancy test , use adequate contraception ( applicable ) 3 . Written inform consent 1 . CD19 negative disease 2 . Overt CNS involvement ( ie : patient CNS2 neurological symptom patient CNS3 ) 3 . Isolated extramedullary disease 4 . Active hepatitis B , C HIV infection 5 . Oxygen saturation ≤ 90 % air 6 . Bilirubin &gt; 3 x upper limit normal 7 . GFR &gt; 50ml/min 8 . Women pregnant breast feed 9 . Stem Cell Transplant patient : active significant acute GVHD ( overall Grade ≥ II , Seattle criterion ) moderate/severe chronic GVHD ( NIH consensus criterion ) require immunosuppressive therapy and/or systemic steroid 10 . Inability tolerate leucapheresis 11 . Karnofsky score &lt; 60 % ( see appendix 3 ) 12 . Patients experience significant neurotoxicity follow blinatumomab 13 . Known allergy albumin DMSO 14 . Life expectancy &lt; 3months</criteria>
	<gender>All</gender>
	<minimum_age>16 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>October 2016</verification_date>
</DOC>